Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 25

1.

Effect of crystallization inhibitors on vascular calcifications induced by vitamin D: a pilot study in Sprague-Dawley rats.

Grases F, Sanchis P, Perelló J, Isern B, Prieto RM, Fernández-Palomeque C, Torres JJ.

Circ J. 2007 Jul;71(7):1152-6.

2.

[Positioning of bisphosphonates for vascular calcification].

Okada Y, Mori H, Tanaka Y, Hashimoto O.

Clin Calcium. 2010 Nov;20(11):1711-7. doi: CliCa101117111717. Review. Japanese.

PMID:
21037392
3.

[Experimental study of the mechanism for vascular calcification in chronic kidney disease].

Persy V.

Verh K Acad Geneeskd Belg. 2008;70(4):285-303. Review. Dutch.

PMID:
19166100
4.

Protective and toxic effects of vitamin D on vascular calcification: clinical implications.

Zittermann A, Koerfer R.

Mol Aspects Med. 2008 Dec;29(6):423-32. doi: 10.1016/j.mam.2008.04.002. Epub 2008 May 1. Review.

PMID:
18538838
5.

Vitamin D and vascular calcification.

Zittermann A, Schleithoff SS, Koerfer R.

Curr Opin Lipidol. 2007 Feb;18(1):41-6. Review.

PMID:
17218831
6.

[Variance of expressions of extracellular matrix components and effects of anti-osteoporotic drugs on Mönckeberg's arteriosclerosis].

Saitoh E, Nagae Y, Wachi H, Seyama Y.

Yakugaku Zasshi. 2008 Mar;128(3):385-92. Review. Japanese.

7.
9.

Bisphosphonates in chronic kidney disease; balancing potential benefits and adverse effects on bone and soft tissue.

Toussaint ND, Elder GJ, Kerr PG.

Clin J Am Soc Nephrol. 2009 Jan;4(1):221-33. doi: 10.2215/CJN.02550508. Epub 2008 Nov 5. Review.

10.
11.

[Bisphosphonates for vascular calcification].

Tanaka Y, Okada Y.

Clin Calcium. 2007 Mar;17(3):386-90. Review. Japanese.

PMID:
17339743
12.

Accelerated atherosclerotic calcification and Monckeberg's sclerosis: a continuum of advanced vascular pathology in chronic kidney disease.

McCullough PA, Agrawal V, Danielewicz E, Abela GS.

Clin J Am Soc Nephrol. 2008 Nov;3(6):1585-98. doi: 10.2215/CJN.01930408. Epub 2008 Jul 30. Review.

13.

Emerging role for the vitamin D receptor activator (VDRA), paricalcitol, in the treatment of secondary hyperparathyroidism.

Cozzolino M, Brancaccio D.

Expert Opin Pharmacother. 2008 Apr;9(6):947-54. doi: 10.1517/14656566.9.6.947. Review.

PMID:
18377338
14.

Importance of calcium, vitamin D and vitamin K for osteoporosis prevention and treatment.

Lanham-New SA.

Proc Nutr Soc. 2008 May;67(2):163-76. doi: 10.1017/S0029665108007003. Review.

PMID:
18412990
15.

Pathogenesis and treatment of secondary hyperparathyroidism in dialysis patients: the role of paricalcitol.

Cozzolino M, Galassi A, Gallieni M, Brancaccio D.

Curr Vasc Pharmacol. 2008 Apr;6(2):148-53. Review.

PMID:
18393917
16.

Vitamin K intake and atherosclerosis.

Erkkilä AT, Booth SL.

Curr Opin Lipidol. 2008 Feb;19(1):39-42. doi: 10.1097/MOL.0b013e3282f1c57f. Review.

PMID:
18196985
17.

[Regulation of calcification by bisphosphonates].

Ono K, Wada S.

Clin Calcium. 2004 Jun;14(6):60-3. Review. Japanese.

PMID:
15577056
18.

A clinical approach to the uraemic patient with extraskeletal calcifications.

Drüeke TB.

Nephrol Dial Transplant. 1996;11 Suppl 3:37-42. Review.

PMID:
8840310
19.

Apoptosis and calcification.

Kim KM.

Scanning Microsc. 1995;9(4):1137-75; discussion 1175-8. Review.

PMID:
8819895
20.

Calcinosis--calcinogenic plants.

Mello JR.

Toxicon. 2003 Jan;41(1):1-12. Review. Erratum in: Toxicon. 2009 Mar 1;53(3):383-4.

PMID:
12467655

Supplemental Content

Support Center